1. Introduction {#sec1}
===============

Neuropsychiatric symptoms of dementia are common and associated with poor outcomes for patients and caregivers \[[@B1]\]. Apathy is the most common neuropsychiatric symptom in mild to moderate stages of Alzheimer\'s disease (AD) and increases in severity as the dementia progresses. Apathy is complex to treat in AD since it is often mixed with other challenging behaviors and confused with depression \[[@B13]\]. A review of scientific evidence shows that pharmacological therapies are not particularly effective for management of these mixed symptoms and further complicated by dangerous side effects \[[@B3]\]. With an estimated 5.5 million Americans with dementia, safe, effective, and easy to deliver therapies are desperately needed for this problem \[[@B1], [@B3]--[@B4]\].

Apathy is defined as the loss of motivation not attributable to cognitive impairment, emotional distress, or reduced level of consciousness \[[@B4]\]. Apathy occurs in approximately 70% of Alzheimer\'s disease (AD) patients within five years of diagnosis \[[@B5]\]. AD patients with apathy require more management and support, given their reliance on others to schedule their activities and initiate tasks even when they are still physically capable of performing them. Studies examining the relationship of apathy to neuropsychological measures showed that apathy was consistently associated with more severe functional impairments, more severe cognitive deficits, higher levels of burden and distress in caregivers, along with increased resource utilization \[[@B6], [@B7]\].

Apathy in early-stage AD is often overlooked by healthcare providers, yet if left untreated, leads to more rapid than expected functional decline \[[@B8]\]. The etiology of apathy is complex and thought to be related to underlying pathology, atrophy of the frontal lobes, and their connections to the temporal lobes \[[@B9]\]. Damage to these areas of the brain reduces the ability to initiate, sequence, and complete tasks. Such losses can lead to unmet needs for cognitive, social, emotional, and physical stimulation.

Older individuals with early-stage memory problems have unmet needs with respect to stimulation, socialization, needs for adaptation of tasks for successful performance, and yet have a desire for novel mentally stimulating experiences to maintain abilities \[[@B13], [@B10]--[@B16]\]. Research shows that patients with Mild Cognitive Impairment (MCI) and early-stage AD continue to respond well to stimulation, often performing at the same levels of brain activity as age-matched controls \[[@B17], [@B18]\]. While the current "state-of-the-art" intervention for early-stage dementia is an early stage support group, those with apathy may not attend or may not benefit in the same way as more motivated participants.

Expanding on Marin\'s Model of Apathy \[[@B19]\] ([Figure 1](#fig1){ref-type="fig"}), we hypothesize that Mentally Stimulating Activities (MSAs) that match current skill levels should be more effective in engaging participants with apathy and early-stage memory loss because they meet individual needs for stimulation while leading to more focused and successful therapeutic experiences. Further, when engaged in MSAs with others, in classroom-style groups, positive emotions should increase and pleasant experiences with others occur. Finally, the physical performance that takes place in each MSA session reduces motor apathy and provides game-like opportunities for active engagement again. These three subcomponents work together to reduce motor, cognitive, and emotional apathy, allow for failure-free enhanced engagement with others, and theoretically could help participants maintain function and improve QOL. This randomized controlled trial (RCT) offered participants either a course in classroom style MSAs or a structured early-stage social support (SS) group for symptoms of early-stage memory loss. This paper will present the impact of a 2-arm RCT cognitive stimulation intervention on apathy, depression, executive function, and cognition in a subset of participants after 4 weeks of intervention. The fully powered complete study will have 120 participants with repeated measures at baseline, four weeks, eight weeks, and 12 weeks.

2. Methods {#sec2}
==========

2.1. Study Design and Participants {#sec2.1}
----------------------------------

The first 77 participants randomized in the trial with pretest and 4-week posttest scores are included in this paper. Randomization by site (*n* = 8 sites) rather than by participant was used to control for possible cross-contamination of treatment or diffusion of effect. The participants to date were recruited from Continuing Care Retirement Communities and local senior centers in central North Carolina and met the following inclusion criteria: English speaking; 60 years of age or older; diagnosis of dementia or symptoms that meet DSM-IV \[[@B20]\] criteria for probable early-stage AD or Peterson criteria for MCI \[[@B21]\]; a Mini-Mental State Exam (MMSE) \[[@B22]\] score of 18 or greater but less than 28; stable on any psychoactive drug from prebaseline through final observation to control for the effect these drugs have on neuropsychiatric behavior; and presence of apathy as reported by family, significant other, or medical provider. Exclusion criteria included delirium or a progressive, unstable medical, metabolic, or neurological illness that might interfere with behavior; recent fracture (within 4 months); history of Parkinson\'s disease, Huntington\'s disease, seizure disorder, major stroke, alcoholism, drug abuse, recent head trauma with loss of consciousness, or psychiatric illness preceding the onset of memory loss; severe vision or hearing impairment; and receiving a new psychoactive medication within the past 30 days. Participants were screened for inclusion by a Geriatric Nurse Practitioner, and for cases without cognitive diagnoses the study PI or medical director was consulted before the participant was included. The IRB of the University of North Carolina at Greensboro provided human subjects approval and data safety and monitoring for this study.

2.2. Mentally Stimulating Activity Program {#sec2.2}
------------------------------------------

The MSA program was developed by Fitzsimmons \[[@B23], [@B24]\] and has been used in community-based, hospital, and long-term care settings by the first and second authors in clinical practice. Specific cognitive tasks target attention, orientation, concentration, short-term memory, and organized thinking in a classroom style setting. In general, activities were designed to be stimulating, challenging, novel, and fun but not frustrating. Each task takes from 2--10 minutes and is interactive and goal driven. The one hour, twice weekly sessions included a variety of physical and cognitive activities that rely on various functions of the brain: visual spatial abilities, verbal and non-verbal communication skills, abstract concepts, eye-hand coordination, fine motor control, body orientation, crossing the midline, recognition memory, short-and long-term memory, executive functioning, and sensory identification. The facilitated tasks were performed by participants alone, in pairs, or as a group. Participants were encouraged to find alternate methods to complete the tasks and were encouraged to help each other.

2.3. Structured Early-Stage Social Support Program {#sec2.3}
--------------------------------------------------

The SS program was developed as a structured psychoeducational group with information about brain health, group discussion, and emotional support provided during each session. The trained facilitator provided the structure and led the discussion. Group members were encouraged to share frustrations, concerns, and thoughts on dealing with the emotional, social, and everyday problems that accompany memory loss. Sessions were provided twice weekly for one hour to provide an equivalent amount of social contact.

3. Data Collection {#sec3}
==================

The following measures of psychological and cognitive functioning were obtained at baseline and after four weeks of the intervention by trained research assistants who were blinded to the participant\'s group assignment: apathy was measured using the Apathy Evaluation Scale (AES) \[[@B19]\]. The AES is an 18-item scale measuring things such as interests, starting and completing things, and initiating activities. Internal consistency is good, with an alpha ranging of 0.86--0.94. Depressive symptoms were measured with the Patient Health Questionnaire (PHQ-9) \[[@B25]\]. The PHQ-9 is a 9-item scale with scores ≥10 having a sensitivity of 88% and a specificity of 88% for major depression. The Cornell-Brown QOL \[[@B26]\] was used to measure quality of life. Interrater reliability (intraclass *r* = 0.90) and internal consistency reliability (Cronbach alpha = 0.81) are very good. Global cognition was measured with the Mini-Mental State Examination (MMSE) which consists of 11 simple questions or tasks. Test-retest reliability is excellent (*r* \> 0.89). Attention and executive functions were measured with the Trail Making test part B \[[@B27]\] ([Table 3](#tab3){ref-type="table"}). [Table 2](#tab2){ref-type="table"} displays evaluation tools used in the study.

3.1. Statistical Methods {#sec3.1}
------------------------

Chi-Square tests and *t*-tests were used to describe the participants by treatment assignment at baseline. To determine the impact of the intervention on outcomes at four weeks, Analysis of Covariance (ANCOVA) was used. Between group differences are presented and adjusted for baseline scores. Statistical analyses were performed with PASW Statistics 18 software. Statistical significance for the study was established at *P* \< .05.

4. Results {#sec4}
==========

Demographics of the first 77 participants are listed in [Table 1](#tab1){ref-type="table"}. The control group (structured social support) had an attrition of eighteen participants (37%) after baseline screening and before the posttest evaluations took place. The treatment group (mentally stimulating activities) had only one drop-out thus the groups reported in this paper are uneven with 29 in control and 48 in treatment due to high SS attrition after intervention assignment. Examining the participants that remained in the study for four weeks, we found no significant difference between groups in baseline age, education, apathy, depression, or MMSE scores. The treatment group had slightly more depressive symptoms on the PHQ-9, slightly more apathy, and slightly poorer quality of life reported on the Cornell-Brown Scale prior to intervention.

After four weeks of intervention, the participants in the MSA group had significantly lower apathy scores than those in the SS group. Specifically, the MSA group dropped 3.9 points on the Apathy Evaluation Scale-Clinical Version and the SS group increased 5.1 points (*P* = .001). Quality of life as measured by the Cornell Brown Scale improved for both groups but the MSA group was significantly better (*P* \< .02). The MSA group improved 8.62 points, and the SS group improved 1.9 points. Participants in the MSA group improved by  .93 on the MMSE (*P* = .001) and the SS group declined by  .62 indicating a significant improvement in cognition occurred for the MSA group after removing the influence of pretest scores. While 57 participants did not indicate depression diagnosis at baseline, a significant change occurred in both groups on the PHQ-9 after four weeks. Participants in the MSA group had a 1.39 point drop, and the SS group had a 1.82 point increase in depression scores (*P* \< .001) after removing the influence of pretest scores. Neither group was significantly different on the Trail Making test.

5. Discussion {#sec5}
=============

In this four-week study of 77 participants with early-stage memory loss and apathy, those taking part in the MSA sessions improved significantly in the areas of apathy, depressive symptoms, and quality of life in comparison to those in the structured social support sessions. A small improvement in mean MMSE score also occurred for the MSA group but the primary target for this study was apathy. We did not find any difference in executive function at week four, but perhaps the intervention will take longer to affect a change in executive function. These improvements are consistent with the findings of earlier studies \[[@B28], [@B29]\]. Our focus on reducing apathy may provide a novel therapeutic route to improving mood and quality of life, and maintaining cognitive function over time. The early-stage support group experienced a 37% attrition rate, and for those that remained at the four week posttest, there was a significant increase in apathy symptoms. These apathy symptoms could explain poorer performance on the evaluation scales.

Most cognitive stimulation or cognitive training trials have targeted healthy older adults and have found improvements on specific tasks \[[@B30]\]. This trial took a different approach with the focus on breaking the pattern of apathy during early stages of memory loss, which other studies have shown to lead to premature functional decline. For people with Alzheimer\'s disease, cognitive stimulation therapy that provides activities involving cognitive processing, within a social context, with an emphasis on enjoyment holds great promise.

There were a number of limitations. It should be noted that this study was limited due to the rigorous inclusion criteria which were necessary to ensure a homogeneous group of participants. This meant many participants with related neurological conditions and complex health problems were excluded. Another limitation was the study sites which were selected by socioeconomic status (SES) (four high SES and four middle to low SES), which allowed diverse senior centers with 3--7 candidates to participate. These small groups enhanced project diversity enrollment but provided less than ideal program sizes which may have influenced outcomes. Recruitment and retention in lower SES sites was a problem. Although groups of 10 were recruited in senior centers, participants did not attend routinely, preferring to take part in other activities or simply not attending after group assignment. Several efforts were made to encourage participation with phone followups, discussions with family or staff members at the sites, but the attrition rate for the control condition was much higher than expected.

In clinical practice, outside of a research trial, participants and groups would be best selected through clinical judgment, considering complexities like sensory impairment, communication deficits, interest, and mix of participants instead of SES and diversity recruitment. In the randomization procedure, ideally the generation of the allocation sequence, enrollment into the trial, and allocation to group should be separate and performed by different, independent staff. The PI and Project Director were directly involved with this process with the statistician due to an initial budget cut from the trial funder.

Many more people are being diagnosed earlier in the course of memory loss because of improving sensitivity and specificity of diagnostic techniques and increased awareness of Alzheimer\'s disease and related disorders. Medical, nursing, allied health professionals, the Alzheimer\'s Association, and other organizations are responding by offering a range of support groups to ease the social strains of people with early-stage dementia. While these support services are needed, it appears that the MSA cognitive stimulation intervention program may be another important option for individuals with early-stage memory changes, especially if they also have apathy symptoms. Offering this type of cognitive stimulation could influence the course of the disease overtime as our early findings show individuals with early-stage memory loss and apathy perform well, improve, and continue to eagerly attend twice per week MSA program sessions.

6. Conclusions {#sec6}
==============

Over 70% of people with early-stage Alzheimer\'s disease experience apathy. This symptom is rarely indentified or treated, which inhibits the older adult\'s ability to remain active with intellectual, interpersonal, and physical activities. In light of the high prevalence of apathy in dementia and its impact on quality of life among older people, the use of MSA cognitive stimulation groups as a means of reducing apathy and depressive symptoms, as well as increasing quality of life is very appealing. Therapists, nurses, and other aging services professionals in community settings can incorporate classroom style cognitive stimulation sessions for clients with dementia and apathy who are underperforming or refusing to participate in other types of therapeutic programs.

The authors wish to thank all who kindly participated in the study in NC, UNCG IRB for compliance review and data safety monitoring, and Alzheimer\'s Association for funding this study (Grant IIRG-09-131429).
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###### 

Participant demographics (values are presented as *n* (%) or mean (standard deviation)).

                         Total        Control (social support)   Treatment (mentally stimulating activities)   *P* value
  ---------------------- ------------ -------------------------- --------------------------------------------- -----------
  *Participants (n*)     77           29\*                       48                                            
  Gender                                                                                                       .243
   Male                  15 (19.5%)   4 (13.8%)                  11 (22.9%)                                    
   Female                62 (80.5%)   25 (86.2%)                 36 (77.1%)                                    
  *Race*                                                                                                       .071
   Caucasian             56 (72.7%)   17 (58.6%)                 39 (81.3%)                                    
   African-American      20 (25.9%)   11 (37.9%)                 9 (18.7%)                                     
   Hispanic              1 (1.3%)     1 (.03%)                   0 (0%)                                        
  *Depression DX*                                                                                              .594
   Yes                   20           7 (24.1%)                  13 (27.1%)                                    
   No                    57           22 (75.9%)                 35 (72.9%)                                    
  *Mean Age*                          82.2 (6.5)                 81.0 (8.7)                                    .07
  *Years of Education*                13.6 (3.8)                 14.6 (3.6)                                    .499
  *Baselines*                                                                                                  
   MMSE                               25.4 (2.8)                 25.2 (3.3)                                    .269
   AES (Apathy)                       30.4 (7.9)                 32.8 (8.7)                                    .331
   Cornell-Brown                      18.6 (11.3)                14.3 (10.8)                                   .758
   PHQ-9                              4.7 (4.8)                  5.9 (5.7)                                     .188
   Trail Making Time                  192.80 (89.7)              178.45 (90.0)                                 .635

\*48 participants were enrolled but 19 dropped after baseline recruitment and evaluation due to health problems and lack of interest in the intervention (39%). These participants were not included in the pre-post analysis.

###### 

Variables and measurement.

  ------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------
  Cognition and Eligibility for study   Mini-Mental State examination (MMSE) \[[@B22]\]                   The MMSE consists of 11 simple questions or tasks. Test-retest reliability (*r* \> 0.89).
  Neuropsychiatric behaviors            Clinician administered Apathy Evaluation Scale (AES) \[[@B19]\]   The AES is an 18-item scale. Internal consistency has an alpha range of 0.86--0.94.Validity: differences found *P* \< .05
  Quality of life                       Cornell-Brown QOL \[[@B24]\]                                      Interrater reliability (intraclass *r* = 0.90) and internal consistency reliability (Cronbach alpha = 0.81).
  Depression                            The Patient Health Questionnaire \[[@B25]\] (PHQ-9)               Nine-item scale with PHQ-9 score ≥10 had a sensitivity of 88% and a specificity of 88% for major depression.
  Executive function                    Trail Making B \[[@B26]\]                                         Validity is high, especially when measuring attention and executive function
  ------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------

###### 

Analyses of covariance summary table for the effect of treatment.

                               Adjusted means at baseline   Adjusted means at 4 weeks   *n*   *F*      Significance (*P* value)
  ------------------- -------- ---------------------------- --------------------------- ----- -------- --------------------------
  Apathy              SS       30.38                        35.52                       29    31.496   \<.001
  MSA                 32.08    28.19                        48                                         
  Cornell Brown QOL   SS       18.62                        20.52                       29    4.978    .029
  MSA                 14.31    22.92                        48                                         
  MMSE                SS       25.41                        24.79                       29    22.429   \<.001
  MSA                 25.17    26.10                        48                                         
  PHQ-9               SS       4.66                         6.48                        29    13.319   \<.001
  MSA                 5.94     4.55                         48                                         
  Trail making        SS       192.20                       178.89                      29    .022     .258 (n.s)
  MSA                 184.73   161.42                       48                                         
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